Q3 2026 Embecta Corp Earnings Call Transcript
Key Points
- Embecta Corp (EMBC) reported significant sequential improvement in Q3 fiscal 2026, with revenue increasing approximately $50 million and adjusted operating income rising about $21 million compared to Q2.
- The Owen Mumford acquisition closed on May 15th and integration is progressing as planned, expanding Embecta Corp (EMBC)'s portfolio into the $2.4 billion auto-injector market with the Adaptus platform.
- Embecta Corp (EMBC) raised its fiscal 2026 adjusted operating margin guidance to 23.5%-24% and adjusted EPS guidance to $1.80-$1.90, driven by cost optimization efforts.
- International business showed strong performance, with revenue increasing 11.5% year-over-year on a reported basis, driven by strength in Latin America and Asia.
- Embecta Corp (EMBC) continues to build commercial momentum with B2B co-packaging opportunities, as generic GLP-1 therapies featuring its pen needles launched in Canada, Brazil, and South Africa.
- The company generated approximately $41 million in free cash flow during Q3 and repaid about $53 million of debt, demonstrating disciplined capital allocation.
- Embecta Corp (EMBC) experienced a year-over-year revenue decline of 8.1% in Q3 fiscal 2026, with U.S. revenue falling 24.6% due to customer and payer mix impacts and lower insulin pen prescriptions.
- Adjusted gross profit margin declined significantly year-over-year, from 67.2% to 58.2%, driven by lower U.S. revenue and inventory adjustments.
- The company faces ongoing pressure from low-cost competitors in the pen needle market, though market-appropriate products are under FDA review.
- U.S. insulin pen prescriptions declined year-over-year at a slightly greater rate in Q3 compared to Q2, with macro factors like ACA enrollment trends and GLP-1 adoption potentially impacting volumes.
- Embecta Corp (EMBC) reaffirmed its revenue guidance of $1,015-$1,035 million, implying a Q4 revenue run-rate of approximately $270 million, which is below current street expectations.
- The company's net leverage stands at 3.7 times, and management has not provided specific revenue expectations for the Adaptus platform, creating uncertainty about future growth contributions.
Welcome, ladies and gentlemen, to Invecta Corporation's fiscal third quarter 2026 earnings conference call.
At this time, all participants are in a listen-only mode. Please note that this conference call is being recorded and a replay will be available on the company's website following the call. Today, Mr. Pravesh Khandalwal, Vice President of Investor Relations. Mr. Khandalwal, please go ahead.
Good morning, everyone, and welcome to MBECTA's Fiscal Third Quarter 2026 Earnings Conference Call. The press release and slides to accompany today's call, along with webcast replay details, are available on the Investor Relations section of our website at www.mbecta.com. With me today are Des Kodekar, MBECTA's Chairman and Chief Executive Officer, and Jake Algouis, our Chief Financial Officer.
Before we begin, I would like to remind you. That some of the matters discussed in the conference call will contain forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
